BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 15927502)

  • 1. [Role of [18F]-fluorodeoxyglucose positron emission tomography for the initial detection, staging, search for recurrences and restaging of gynaecological and breast cancers].
    Grahek D; Barranger E; Daraï E; Uzan S; Talbot JN
    Gynecol Obstet Fertil; 2005 Jun; 33(6):371-81. PubMed ID: 15927502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET imaging in gynecologic malignancies.
    Kumar R; Alavi A
    Radiol Clin North Am; 2004 Nov; 42(6):1155-67, ix. PubMed ID: 15488564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Utilization of PET scan in breast and gynaecologic cancers].
    Huglo D; Vinatier D
    Gynecol Obstet Fertil; 2004 Apr; 32(4):330-9. PubMed ID: 15123104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Update of 'standards, options and recommendations' for FDG-PET in breast and gynaecological cancers].
    Talbot JN; Grahek D
    Gynecol Obstet Fertil; 2006 May; 34(5):434-6. PubMed ID: 16677841
    [No Abstract]   [Full Text] [Related]  

  • 5. [2003 update of recommendations for clinical practice: standards, options and recommendations for the use of FDG-PET in the management of gynaecological and breast cancers].
    FNCLCC
    Gynecol Obstet Fertil; 2004 Apr; 32(4):352-71. PubMed ID: 15123109
    [No Abstract]   [Full Text] [Related]  

  • 6. Positron emission tomography in gynecological malignancies.
    Kumar R; Chauhan A; Jana S; Dadparvar S
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):1033-44. PubMed ID: 16831075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [(18F)-fluoro-2-deoxyglucose PET in imaging of gynecologic cancers].
    Talbot JN; Grahek D; Kerrou K; Younsi N; de Beco V; Colombet-Lamau C; Petegnief Y; Cailleux N; Montravers F
    Gynecol Obstet Fertil; 2001 Nov; 29(11):775-98. PubMed ID: 11770272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG-PET in gynaecological cancers: recent observations.
    Lucignani G
    Eur J Nucl Med Mol Imaging; 2008 Nov; 35(11):2133-9. PubMed ID: 18779962
    [No Abstract]   [Full Text] [Related]  

  • 9. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET.
    Torizuka T; Kanno T; Futatsubashi M; Okada H; Yoshikawa E; Nakamura F; Takekuma M; Maeda M; Ouchi Y
    J Nucl Med; 2003 Jul; 44(7):1051-6. PubMed ID: 12843219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of PET Imaging in Gynecologic Radiation Oncology.
    Rao YJ; Grigsby PW
    PET Clin; 2018 Apr; 13(2):225-237. PubMed ID: 29482751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Synthesis bulletin of 2005 surveillance. Clinical practice recommendations: the use of PET-FDG in cancers of the breast, ovary and uterus].
    Bourguet P; Hitzel A; Houvenaeghel G; Vinatier D; Bosquet L; Bonichon F; Corone C; Giard-Lefèvre S; Morett JL; Touboul E; ; ; ; ; ; ; ;
    Bull Cancer; 2006 Apr; 93(4):385-90. PubMed ID: 16714228
    [No Abstract]   [Full Text] [Related]  

  • 12. Positron emission tomography scanning in gynecologic and breast cancers.
    Zimny M; Siggelkow W
    Curr Opin Obstet Gynecol; 2003 Feb; 15(1):69-75. PubMed ID: 12544505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Metabolic imaging with positron-emission tomography in the advanced-stage ovarian cancers].
    Grahek D; Hassan-Sebbag N
    Bull Cancer; 2009 Dec; 96(12):1163-71. PubMed ID: 19948451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative Assessment of Gynecologic Malignancies.
    Tripathy S; Parida GK; Kumar R
    PET Clin; 2018 Apr; 13(2):269-288. PubMed ID: 29482754
    [No Abstract]   [Full Text] [Related]  

  • 15. PET/CT in gynecologic malignancies.
    Brunetti J
    Radiol Clin North Am; 2013 Sep; 51(5):895-911. PubMed ID: 24010912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG-PET Assessment of Other Gynecologic Cancers.
    Faria S; Devine C; Viswanathan C; Javadi S; Korivi BR; Bhosale PR
    PET Clin; 2018 Apr; 13(2):203-223. PubMed ID: 29482750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gynecological cancers.
    Avril N; Gourtsoyianni S; Reznek R
    Methods Mol Biol; 2011; 727():171-89. PubMed ID: 21331934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Positron emission tomography with 18F-fluorodeoxyglucose in patients with uterine sarcoma].
    Rebollo Aguirre AC; Ramos Font C; Bellón Guardia ME; Cabello García D; Gallego Peinado M; Rodríguez Fernández A; Llamas Elvira JM
    Rev Esp Med Nucl; 2007; 26(4):189-95. PubMed ID: 17662185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of fluorodeoxyglucose positron emission tomography in women with breast cancer.
    Landheer ML; Steffens MG; Klinkenbijl JH; Westenberg AH; Oyen WJ
    Br J Surg; 2005 Nov; 92(11):1363-7. PubMed ID: 16187254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.